VectorY Therapeutics Appoints Kevin Pojasek, Ph.D., to Board of Directors
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: Business Wire
Experienced biotech executive brings more than 20 years of leadership experience in company creation, strategy, and drug development AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectoryY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today the appointment of Kevin Pojasek, Ph.D., to its Board of Directors. Dr. Pojasek brings more than two decades of expertise founding, scaling, and leading innovative biopharma companies, with deep expertise across corporate strategy, business development, and research and development.Dr. Pojasek is currently president and chief executive officer of Enara Bio, where he has led the company since 2018 and advanced its vision to develop T-cell engager therapies against novel solid tumor targets. He is also a Venture Partner at SV Health Investors and previously served as an Entrepreneur-in-Residence at Atlas Venture.Prior to Enara, Dr. Pojasek was chief strategy and business officer at Immunocore, where he pla
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- Immunocore (NASDAQ:IMCR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- Levicept Announces the Appointment of James Sandy as Chief Development Officer [Yahoo! Finance]Yahoo! Finance
- Levicept Announces the Appointment of James Sandy as Chief Development OfficerGlobeNewswire
- Assessing Immunocore Holdings (IMCR) Valuation After Recent Share Price Volatility [Yahoo! Finance]Yahoo! Finance
- Moderna Refocuses On Rare Diseases As New Leadership Shapes Pipeline [Yahoo! Finance]Yahoo! Finance
IMCR
Earnings
- 11/6/25 - Beat
IMCR
Sec Filings
- 1/30/26 - Form 8-K
- 1/9/26 - Form 8-K
- 12/8/25 - Form 4
- IMCR's page on the SEC website